Patients with Unresectable Stage III Non-Small Cell Lung Cancer Eligible to Receive Durvalumab in Clinical Practice

被引：0
|
作者：
Furuhashi, K. [1 ]
Hataji, O. [1 ]
Nakamura, Y. [1 ]
Suzuki, Y. [1 ]
Sakaguchi, T. [1 ]
Ito, K. [1 ]
Fujiwara, K. [1 ]
Nishii, Y. [1 ]
Taguchi, O. [1 ]
机构：
[1] Matsusaka Municipal Hosp, Resp Ctr, Matsusaka City, Mie, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
chemoradiotherapy; durvalumab; Non-Small Cell Lung Cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP1.18-19
引用
收藏
页码：S1104 / S1104
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer
    Bunn, Paul A., Jr.
    Gaspar, Laurie E.
    Weyant, Michael J.
    Mitchell, John D.
    CANCER, 2016, 122 (05) : 674 - 675
  • [42] Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC)
    Raben, D.
    Rimner, A.
    Senan, S.
    Broadhurst, H.
    Pellas, T.
    Dennis, P. A.
    Faivre-Finn, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (03): : 683 - 683
  • [43] Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer
    Edwards, Donna M.
    Sankar, Kamya
    Alseri, Aaren
    Jiang, Ralph
    Schipper, Matthew
    Miller, Sean
    Dess, Kathryn
    Strohbehn, Garth W.
    Moghanaki, Drew
    Ramnath, Nithya
    Green, Michael D.
    Bryant, Alex K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (04): : 963 - 970
  • [44] Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?
    De Ruysscher, Dirk
    Remon, Jordi
    Hendriks, Lizza E. L.
    EUROPEAN JOURNAL OF CANCER, 2022, 167 : 149 - 151
  • [45] Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer
    Chiramel, Jaseela
    Tay, Rebecca
    Califano, Raffaele
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S991 - S994
  • [46] Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC)
    Socinski, Mark A.
    Ozguroglu, Mustafa
    Villegas, Augusto
    Daniel, Davey
    Vicente, David
    Murakami, Shuji
    Hui, Rina
    Gray, Jhanelle E.
    Park, Keunchil
    Vincent, Mark
    Mann, Helen
    Newton, Michael
    Dennis, Phillip A.
    Antonia, Scott J.
    CLINICAL LUNG CANCER, 2021, 22 (06) : 549 - 561
  • [47] Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer
    Haratani, Koji
    Nakamura, Atsushi
    Mamesaya, Nobuaki
    Sawa, Kenji
    Shiraishi, Yoshimasa
    Saito, Ryota
    Tanizaki, Junko
    Tamura, Yosuke
    Hata, Akito
    Tsuruno, Kosuke
    Sakamoto, Tomohiro
    Teraoka, Shunsuke
    Oki, Masahide
    Watanabe, Hiroshi
    Tokito, Takaaki
    Nagata, Kenji
    Masuda, Takeshi
    Nakamura, Yasushi
    Sakai, Kazuko
    Chiba, Yasutaka
    Ito, Akihiko
    Nishio, Kazuto
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    Hayashi, Hidetoshi
    BRITISH JOURNAL OF CANCER, 2024, 130 (11) : 1783 - 1794
  • [48] Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer
    Stevens, Samuel
    Nindra, Udit
    Shahnam, Adel
    Wei, Joe
    Bray, Victoria
    Pal, Abhijit
    Yip, Po Yee
    Linton, Anthony
    Blinman, Prunella
    Nagrial, Adnan
    Lee, Jenny
    Boyer, Michael
    Kao, Steven
    JOURNAL OF GERIATRIC ONCOLOGY, 2024, 15 (02)
  • [49] Treatment interruptions and discontinuations among patients with stage III unresectable non-small cell lung cancer treated with durvalumab at the Veterans Health Administration.
    Alkadimi, Munaf
    Moore, Amanda
    Frei, Christopher R.
    Reveles, Kelly R.
    Brannman, Lance
    Cotarla, Ion
    Frankart, Andrew
    Mulrooney, Tiernan
    Datta, Paromita
    Whitehead, Jennifer
    Franklin, Kathleen
    Reichelderfer, Renee
    Williams, Madison H.
    Williams, Ryan A.
    Smith, Sarah Allison
    Jones, Xavier
    Nooruddin, Zohra
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] Durvalumab treatment initiation delays in patients with unresectable stage III non-small cell lung cancer treated at Veterans Health Administration facilities.
    Datta, Paromita
    Moore, Amanda
    Frei, Christopher R.
    Reveles, Kelly R.
    Brannman, Lance
    Cotarla, Ion
    Frankart, Andrew
    Mulrooney, Tiernan
    Alkadimi, Munaf
    Whitehead, Jennifer
    Franklin, Kathleen
    Reichelderfer, Renee
    Williams, Madison H.
    Williams, Ryan A.
    Smith, Sarah Allison
    Jones, Xavier
    Nooruddin, Zohra
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345